Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐based pharmacokinetic model

Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐based pharmacokinetic model

Abstract Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patients with heart failure. The potential for a pharmac...

Full description

Saved in:
Bibliographic Details
Main Authors: Ashit Trivedi, Winnie Sohn, Priyanka Kulkarni, Pegah Jafarinasabian, Hanze Zhang, Marintan Spring, Stephen Flach, Siddique Abbasi, Jan Wahlstrom, Edward Lee, Sandeep Dutta
Format: article
Language:EN
Published: Wiley 2021
Subjects:
Therapeutics. Pharmacology
RM1-950
Public aspects of medicine
RA1-1270
Online Access:https://doaj.org/article/86aa2e97af2349d6999630760b8de569
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/86aa2e97af2349d6999630760b8de569

Similar Items